(PharmaNewsWire.Com, June 23, 2017 ) The report "Spine Biologics Market by Product Type (Bone Graft, Bine Graft Substitute, Platelet Rich Plasma, BMAC), Surgery Type (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), End User, and Geography - Global Forecast to 2020", the global spine biologics market was valued at $1.90 Billion in 2014 and is expected to reach $2.4 Billion by 2020, at a CAGR of 4.4% during the forecast period of 2015 to 2020. Browse 55 market data tables and 54 figures spread through 101 pages and in-depth TOC on "Spine Biologics Market” <||>rnhttp://www.marketsandmarkets.com/Market-Reports/spine-biologics-market-67680943.html Early buyers will receive 10% customization on This report.
Spinal biologics encompass materials that can be utilized in case of bone fusion surgery, spinal cord injury, and degenerative disk disease. Ten years ago, the spine treatment market constituted 75% traditional rods and plates made of metals and 25% biologics.
However, since metals are inert materials, they did not stimulate the bone regeneration process. On the other hand, biological materials are proteins that can attract and stimulate cells, promote fusion, and help in the bone healing process
By product type, the spine biologics market is categorized into four types, namely, bone graft substitutes, bone grafts, platelet-rich plasma (PRP), and bone marrow aspirate concentrate therapy. In 2014, the bone graft substitutes segment contributed the largest share of 84.1% to the global market.
By surgery type, the market is segmented into: anterior cervical discectomy and fusion (ACDF), transforaminal lumbar interbody fusion (TLIF), anterior lumbar interbody fusion (ALIF), lateral lumbar interbody fusion (LLIF), and other surgeries. The ACDF segment contributed the largest share to the global spine biologics market in 2014, followed by the transforaminal lumbar interbody fusion (TLIF) segment.
The spine biologics devices are used in spine surgery as lieu allografts as well as a support for bones in and around the spinal region. These devices offer numerous benefits over materials such as pedicle rods and screws that are used in spine fusion. Since metals are inert in nature, they do not stimulate or activate cellular growth or alter cellular functions such as natural healing. Spine biologics, on the other hand, activate cellular growth by stimulating spine fusion.
The driving forces for global spinal biologics market include rising incidence of spinal disorders, rising healthcare expenditure in developing nations owing to growing income levels, rising obesity cases, awareness on the newly developed spine treatment techniques and devices, technological advancements, and rising demand of minimally invasive spine surgeries. The major restraints for this market include lack of expertise, lack of patient awareness, cost of surgery, and unfavourable reimbursement scenario.
The global spine biologics market has been categorized by regions into North America, Europe, Asia-Pacific, and the Rest of the World. North America is the most dominant region in the global market, followed by Europe. Bone graft substitute segment dominated the North American spine biologics market.
Some of the major players in the spine biologics market are Medtronic Inc. (U.S.), DePuy Synthes Companies (U.S.), Zimmer Holding Inc. (U.S.), Nuvasive Inc. (U.S.), Stryker Corporation (U.S.), Orthofix international N.V. (U.S.), K2M Inc. (U.S.), Exactech Inc. (U.S.), Wright Medical Technology Inc. (U.S.), and others.
About MarketsandMarkets™: MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact: Mr. Rohan MarketsandMarkets™ 701 Pike Street Suite 2175, Seattle, WA 98101, United States Tel: 1-888-600-6441
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
